Minerva Neurosciences, Inc. — Q1 2023 Form 10-Q
Reporting period: Three months ended March 31, 2023; filed May 15, 2023. The unaudited statements compare with Q1 2022.
Business context and key financial metrics
Minerva is a clinical-stage biopharmaceutical company with no approved products and no product revenue. Its lead candidate, roluperidone, is being developed for negative symptoms of schizophrenia; it also holds rights to MIN-301 for Parkinson’s disease.
| Metric | Q1 2023 | Q1 2022 / prior balance |
|---|---|---|
| Revenue | None | None |
| Research and development expense | $2.65 million | $4.96 million |
| General and administrative expense | $2.69 million | $3.03 million |
| Total expenses / operating loss | $5.35 million | $7.99 million |
| Net loss | $6.97 million | $9.76 million |
| Basic and diluted loss per share | $1.31 | $1.83 |
| Net cash used in operating activities | $0.12 million | $5.81 million |
| Cash, cash equivalents and restricted cash | $36.08 million | $36.19 million at Dec. 31, 2022 |
| Total assets | $51.59 million | $55.09 million at Dec. 31, 2022 |
| Total liabilities | $78.21 million | $75.11 million at Dec. 31, 2022 |
| Stockholders’ deficit | $26.62 million | $20.02 million at Dec. 31, 2022 |
There was no investing or financing cash flow in either quarter. No gross margin is reported because the company had no revenue. The filing does not report conventional bank debt; its $75.71 million liability for the sale of future seltorexant royalties is accounted for as debt and increased by $1.98 million of non-cash interest expense in Q1. The estimated effective annual interest rate was approximately 10.7%.
Changes versus the comparable period
- Net loss narrowed by about $2.79 million, with operating expenses down about $2.64 million. R&D expense fell mainly because of lower stock-based compensation and NDA-related consultant fees; G&A declined mainly due to lower stock compensation.
- Investment income rose to $364,000 from $7,000, primarily reflecting higher interest rates. Non-cash royalty-obligation interest expense increased to $1.98 million from $1.78 million.
- Operating cash use fell to $115,000 from $5.81 million. The 2023 figure benefited substantially from receipt of the $3.12 million FDA user-fee refund, as well as other working-capital changes and non-cash adjustments; it should not be read as the company’s recurring cash burn.
- Cash and cash equivalents declined slightly from year-end, while the royalty liability and accumulated deficit increased. Accrued expenses rose to $1.54 million from $408,000.
Outlook, commentary and material risks
- After quarter-end, the FDA filed the roluperidone NDA on April 27, 2023, following Minerva’s appeal of the October 2022 refusal-to-file decision. On May 8, the FDA assigned standard review and a PDUFA goal date of February 26, 2024. The FDA identified potential review issues previously raised, including antipsychotic interaction/safety, applicability of non-U.S. study data to U.S. patients, efficacy evidence, and identifying likely responders. Filing does not assure approval.
- Management said the $36.1 million of cash, cash equivalents and restricted cash was expected to fund operating commitments for at least 12 months from the financial-statement issuance date. The company expects continued losses and negative operating cash flows and says additional capital will be needed to continue operations and fully fund later-stage development. Financing may be unavailable or unfavorable; operations could be scaled back or discontinued if funds cannot be raised.
- Minerva had a Nasdaq deficiency notice for market value of listed securities below $35 million, with a compliance deadline of May 30, 2023. Failure to regain compliance could lead to delisting and impair access to capital. The filing does not state the subsequent outcome.
- Janssen was conducting two Phase 3 seltorexant studies; a third had been discontinued in 2022. Up to $95 million in potential royalty-sale milestone payments depends on clinical, regulatory and commercial events and is not assured.
- The filing highlights clinical and regulatory uncertainty, funding needs, potential dilution, product-development and commercialization risks, Nasdaq listing risk, and data privacy and cybersecurity risks. It reports no legal proceeding expected to have a material adverse effect.
- On April 28, 2023, the compensation committee certified the NDA-acceptance condition for the performance-based stock units; 50% vested. The filing reports 5,568,406 shares outstanding as of May 10, versus 5,340,193 at March 31.
No formal financial or product-sales guidance is provided. Management said spending can be adjusted based on clinical-trial timing and available resources.
Important facts for investors to verify
- Current FDA review status, remaining roluperidone review issues, and whether additional studies or a complete response are required before the February 26, 2024 PDUFA goal date.
- Cash runway using recurring operating expenditures, excluding the one-time FDA fee refund, and the timing and terms of any future financing.
- Nasdaq market-value compliance status and any subsequent listing decision or extension.
- Progress and outcomes of Janssen’s two Phase 3 seltorexant studies and the conditions for any milestone payments.
- Share-count changes, including the impact of vested performance-based units and any future at-the-market equity sales; $22.6 million remained eligible for sale under the ATM program at March 31.